Regeneron Pharmaceuticals (REGN) Net Cash Flow (2009 - 2026)

Regeneron Pharmaceuticals' Net Cash Flow history runs 18 years deep, the most recent figure standing at -$152.2 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 125.22% year-over-year to -$152.2 million; the TTM figure through Mar 2026 stood at -$121.2 million (down 125.1% YoY), while the FY2025 annual figure was $634.4 million, up 355.7% from the prior year.
• Net Cash Flow was -$152.2 million for Q1 2026 at Regeneron Pharmaceuticals, down from $610.9 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $809.4 million in Q1 2023 to a low of -$2.0 billion in Q2 2023.
• Historically, Net Cash Flow has averaged $4.4 million across 5 years, with a median of $96.2 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Net Cash Flow sank 4105.47% in 2023, then jumped 573.25% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$385.4 million in 2022, then soared by 249.82% to $577.4 million in 2023, then slipped by 17.23% to $477.9 million in 2024, then increased by 27.83% to $610.9 million in 2025, then slumped by 124.91% to -$152.2 million in 2026.
• The last three Net Cash Flow figures came in at -$152.2 million (Q1 2026), $610.9 million (Q4 2025), and $497.9 million (Q3 2025), per Business Quant data.